Johnson & Johnson Reports Earnings Beat but GAAP Profit Plummets, Sending Stock Down
Despite reporting better-than-expected earnings for Q3 and raising its full-year guidance in October 2026, Johnson & Johnson (JNJ) saw its stock fall by nearly 7% due to a significant drop in GAAP profit. The company reported adjusted earnings of $2.59 per share on sales of $25.4 billion for the quarter, slightly above expectations. However, J&J's GAAP earnings plummeted year-over-year to just $0.09 per share — a 96% decline attributed to one-time charges related to litigation and acquisitions. Investors were disappointed by these results despite an increase in free cash flow of over 6%, reaching $15.1 billion, and the company's updated guidance for higher sales growth through 2026. Analysts remain skeptical about whether J&J’s projected performance justifies its current valuation metrics.
Tickers: $JNJ
Topics: earnings pharmaceuticals stock_performance
Read the full article at Motley Fool
Part of the story JOHNSON & JOHNSON - 8-K Filing (37 articles)